UPCOMING EVENTS
NEWS
ErythroMer in the News: Making and storing blood to save lives
KaloCyte co-founders Allan Doctor and Dipanjan Pan are featured in an article titled, “Making and storing blood to save lives”
Press Release: KaloCyte Welcomes Lyophilization Expert to its Baltimore Headquarters
KaloCyte welcomes Product Development Scientist, Nivesh Mittal, PhD to propel production of ErythroMer™
Maryland Booms in the BioCapital Hotbed
Elaine E. Haynes, President and CEO of KaloCyte, Inc., featured in BioSpace article touting Maryland, a BioCapital hotbed.
Elaine Haynes Discusses Business in Maryland with the Maryland Tech Council
In this episode, Marty discusses business in Maryland with Elaine E. Haynes, President and CEO of KaloCyte, Inc., a pre-clinical biotech startup developing a synthetic red blood cell substitute.
Press Release: KaloCyte CEO to Present at NIH Innovation Conference and Life Sciences Summit
KaloCyte, Inc., a preclinical-stage healthcare biotechnology company developing a synthetic, bio-inspired red blood cell substitute for use in settings when stored red blood cells are not available, has been selected to present this week at both the National Institutes of Health (NIH) Innovation Conference (NIC) and the Life Sciences Summit (LSS) in New York City.
Bold New Vision on Blood Research
New Center for Blood Oxygen Transport & Hemostasis will develop diagnostics and therapeutics that could revolutionize emergency and critical care medicine.
Why KaloCyte Picked Baltimore and the BioPark
The BioPark also offers a community of people who are working on similar companies in similar areas.
“We’re delighted to be here,” Haynes said. “It’s been clear that the community is happy to have us here and is motivated to help us be successful, the university in particular.”
Baltimore’s proximity to key stakeholders, like research institutions and the government, also played a role in the move, Haynes said.
St. Louis biotech company moves to Baltimore to develop fake blood for real emergencies
A small biotechnology company developing a synthetic blood for use when supplies are low or unavailable is moving to Baltimore from St. Louis and affiliating with the University of Maryland BioPark.
During a trauma, blood loss is the leading cause of preventable death, but bags of blood aren’t always available, such as on the battlefield or at a mass casualty scene. There is no real blood substitute, though some products are in the works.
ErythroMer, the blood product created by the Missouri biotechnology firm KaloCyte, is in development and could be tested in humans in two to three years, the company reports. If proved safe and effective, it could become the only such blood substitute able to be freeze-dried for longer-term storage and transport.
That would make ErythroMer more useful in military or domestic trauma settings, as well as in developing countries, company officials said.
Why Baltimore rose to the ‘top of the list’ when this biotech needed a new HQ
As announced last week, the team that is commercializing a synthetic blood product relocated from St. Louis to downtown Baltimore, with the company taking up residence at UMB and joining the University of Maryland BioPark as an affiliate.
Nearby, at the campus’ University of Maryland School of Medicine (UMSOM), cofounder Chief Scientific Officer Dr. Allan Doctor is directing the recently formed Center for Blood Oxygen Transport & Hemostasis (CBOTH), while cofounder Dr. Dipanjan Pan is leading nanobiofabrication at the center and become a professor at UMSOM and University of Maryland, Baltimore County.
KaloCyte joins as an affiliate of the university’s BioPark, or biomedical research park, with the goal of bringing its synthetic red blood cell substitute to market. The product, called ErythroMer, is designed to take the place of blood in trauma situations or other times when it may be unavailable.
St. Louis biotech KaloCyte joins UM BioPark, consolidates team in Baltimore
A St. Louis biotechnology company backed by $6 million in funding has relocated to a small space in one of the University of Maryland, Baltimore’s research facilities.
KaloCyte joins as an affiliate of the university’s BioPark, or biomedical research park, with the goal of bringing its synthetic red blood cell substitute to market. The product, called ErythroMer, is designed to take the place of blood in trauma situations or other times when it may be unavailable.
QUICK LINKS
ABOUT US
KaloCyte was founded by a distinguished team of researchers in physiology, bioengineering, and trauma care and is poised to deliver ErythroMer, a dried, bio-inspired artificial red blood cell, to market. ErythroMer is envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by over $20M in federal grants and investor funding.